Literature DB >> 10616207

Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells.

C Herold-Mende1, H H Steiner, T Andl, D Riede, A Buttler, C Reisser, N E Fusenig, M M Mueller.   

Abstract

Vascular endothelial growth factor (VEGF) is one of the key factors in tumor neoangiogenesis, acting through its receptors KDR (VEGFR-2) and fit-1 (VEGFR-1) expressed on endothelial cells. Our data demonstrate that VEGFR-1 and to a lesser extent VEGFR-2 are expressed in a number of human tumor tissues and derived cells in culture. VEGFR-1 protein is expressed in 26 of 42 glioma tissues, 22 of which show a coexpression of VEGFR-1 with VEGFR-2; 1 glioma tissue expresses exclusively VEGFR-2. In the derived glioma cell cultures, we found VEGFR-1 mRNA expression in 6 of 11 cultures, with one coexpressing VEGFR-1 and VEGFR-2. Of four established glioma cell lines, two expressed VEGFR-1. In addition VEGFR-1 protein expression was demonstrated in 30 of 37 tumor tissues of squamous cell carcinomas of the head and neck, with VEGFR-2 coexpression in 15 tissues and an expression of VEGFR-2 alone in 1 tissue. Derived tumor cell cultures showed mRNA expression of VEGFR-1 alone in seven of seven cases. Established melanoma cell lines expressed VEGFR-1 mRNA in four of five lines, with VEGFR-2 coexpression in two lines. Concerning the functional significance of VEGF receptor expression, VEGF treatment of VEGFR-1-expressing tumor cells induced the inhibition of cell proliferation by 25 to 55% and the inhibition of tumor cell migration by 29 to 55%. Thus our data indicate that the coexpression of VEGF and VEGFR-1 in tumor cells could have an inhibitory effect on tumor cell proliferation and migration, a mechanism possibly induced as a response to a deficiency in nutrient and oxygen supply.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10616207

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  27 in total

1.  Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.

Authors:  Philipp Beckhove; Rolf Warta; Britt Lemke; Diana Stoycheva; Frank Momburg; Martina Schnölzer; Uwe Warnken; Hubertus Schmitz-Winnenthal; Rezvan Ahmadi; Gerhard Dyckhoff; Mariana Bucur; Simone Jünger; Thomas Schueler; Volker Lennerz; Thomas Woelfel; Andreas Unterberg; Christel Herold-Mende
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.

Authors:  S Dias; K Hattori; B Heissig; Z Zhu; Y Wu; L Witte; D J Hicklin; M Tateno; P Bohlen; M A Moore; S Rafii
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

5.  siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer.

Authors:  Donglei Zhou; Xun Jiang; Weixing Ding; Lijun Zheng; Lei Yang; Chengzhu Zheng; Liesheng Lu
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-28       Impact factor: 4.553

6.  Functional significance of vascular endothelial growth factor receptor expression on human glioma cells.

Authors:  Rolf Mentlein; Frauke Forstreuter; Hubertus M Mehdorn; Janka Held-Feindt
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.

Authors:  Nader Rahimi; Todd E Golde; Rosana D Meyer
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

8.  Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells.

Authors:  Matteo Di Piazza; Carmen Mader; Karsten Geletneky; Marta Herrero Y Calle; Ekkehard Weber; Jörg Schlehofer; Laurent Deleu; Jean Rommelaere
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6.

Authors:  Yoshiko Aoyagi; Hisae Iinuma; Atsushi Horiuchi; Ryu Shimada; Toshiaki Watanabe
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

Review 10.  Angiogenesis factors in gliomas: a new key to tumour therapy?

Authors:  Rolf Mentlein; Janka Held-Feindt
Journal:  Naturwissenschaften       Date:  2003-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.